Athena Athena

X
[{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Microba Life Sciences and Ginkgo Bioworks Announce Partnership to Discover Novel Live Biotherapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery"},{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Garvan Institute of Medical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microba Accelerates Cancer Program With New Leads","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"AUSTRALIA","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Bacthera","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microba Commences Phase I Clinical Trial for IBD Therapeutic","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by Microba Life Sciences

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            MAP 315 is a live biotherapeutic product (LBP) consisting of lyophilised bacteria in an enteric coated capsule which is orally administered and being developed as an investigational product for the treatment of IBD and ulcerative colitis (UC).

            Lead Product(s): MAP 315

            Therapeutic Area: Gastroenterology Product Name: MAP 315

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Bacthera

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 27, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Microba’s Cancer Immuno-Oncology Neoadjuvant Therapy is targeting discovery and development of a microbiome therapy to improve response rates in cancer patients receiving immune checkpoint inhibitor (ICI) therapy, with a specific focus on Melanoma and Lung cancer patients.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Garvan Institute of Medical Research

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 04, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration aims to build on Microba’s precision approach to LBP development with an in-depth evaluation of the company’s strains using Ginkgo’s high throughput, automatedscreening capabilities.

            Lead Product(s): Microbiome Based Product

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ginkgo Bioworks

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership April 04, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY